nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—PLA2G4A—Epirubicin—urinary bladder cancer	0.411	0.859	CbGbCtD
Orlistat—CYP3A4—Thiotepa—urinary bladder cancer	0.0463	0.0968	CbGbCtD
Orlistat—CYP3A4—Etoposide—urinary bladder cancer	0.0125	0.0262	CbGbCtD
Orlistat—DAGLB—prostate gland—urinary bladder cancer	0.0122	0.0819	CbGeAlD
Orlistat—PLA2G7—prostate gland—urinary bladder cancer	0.00986	0.0661	CbGeAlD
Orlistat—ABHD16A—prostate gland—urinary bladder cancer	0.00925	0.0621	CbGeAlD
Orlistat—ABHD12—prostate gland—urinary bladder cancer	0.00867	0.0582	CbGeAlD
Orlistat—CYP3A4—Doxorubicin—urinary bladder cancer	0.00855	0.0179	CbGbCtD
Orlistat—PLA2G7—seminal vesicle—urinary bladder cancer	0.00834	0.0559	CbGeAlD
Orlistat—ABHD16A—seminal vesicle—urinary bladder cancer	0.00782	0.0525	CbGeAlD
Orlistat—ABHD12—seminal vesicle—urinary bladder cancer	0.00733	0.0492	CbGeAlD
Orlistat—FASN—prostate gland—urinary bladder cancer	0.00727	0.0488	CbGeAlD
Orlistat—ABHD16A—urethra—urinary bladder cancer	0.00619	0.0416	CbGeAlD
Orlistat—FASN—seminal vesicle—urinary bladder cancer	0.00615	0.0413	CbGeAlD
Orlistat—ABHD12—urethra—urinary bladder cancer	0.0058	0.0389	CbGeAlD
Orlistat—PLA2G7—vagina—urinary bladder cancer	0.00487	0.0326	CbGeAlD
Orlistat—PNLIP—female reproductive system—urinary bladder cancer	0.00473	0.0317	CbGeAlD
Orlistat—ABHD16A—vagina—urinary bladder cancer	0.00457	0.0306	CbGeAlD
Orlistat—ABHD12—vagina—urinary bladder cancer	0.00428	0.0287	CbGeAlD
Orlistat—DAGLB—lymph node—urinary bladder cancer	0.0039	0.0261	CbGeAlD
Orlistat—FASN—vagina—urinary bladder cancer	0.00359	0.0241	CbGeAlD
Orlistat—PLA2G4A—prostate gland—urinary bladder cancer	0.0035	0.0235	CbGeAlD
Orlistat—PLA2G4A—Raltitrexed—Methotrexate—urinary bladder cancer	0.00345	0.633	CbGdCrCtD
Orlistat—CYP3A4—urine—urinary bladder cancer	0.00321	0.0216	CbGeAlD
Orlistat—PLA2G7—lymph node—urinary bladder cancer	0.00315	0.0211	CbGeAlD
Orlistat—PLA2G4A—seminal vesicle—urinary bladder cancer	0.00296	0.0198	CbGeAlD
Orlistat—ABHD16A—lymph node—urinary bladder cancer	0.00295	0.0198	CbGeAlD
Orlistat—ABHD12—lymph node—urinary bladder cancer	0.00277	0.0186	CbGeAlD
Orlistat—PLA2G4A—smooth muscle tissue—urinary bladder cancer	0.00248	0.0166	CbGeAlD
Orlistat—PLA2G4A—renal system—urinary bladder cancer	0.00238	0.016	CbGeAlD
Orlistat—PLA2G4A—urethra—urinary bladder cancer	0.00234	0.0157	CbGeAlD
Orlistat—FASN—lymph node—urinary bladder cancer	0.00232	0.0156	CbGeAlD
Orlistat—FASN—Azacitidine—Gemcitabine—urinary bladder cancer	0.002	0.368	CbGdCrCtD
Orlistat—PLA2G4A—female reproductive system—urinary bladder cancer	0.00191	0.0128	CbGeAlD
Orlistat—PLA2G4A—vagina—urinary bladder cancer	0.00173	0.0116	CbGeAlD
Orlistat—PLA2G4A—lymph node—urinary bladder cancer	0.00112	0.00749	CbGeAlD
Orlistat—CYP3A4—renal system—urinary bladder cancer	0.000786	0.00527	CbGeAlD
Orlistat—CYP3A4—female reproductive system—urinary bladder cancer	0.00063	0.00422	CbGeAlD
Orlistat—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00023	0.00106	CcSEcCtD
Orlistat—Infestation NOS—Methotrexate—urinary bladder cancer	0.00023	0.00106	CcSEcCtD
Orlistat—Infestation—Methotrexate—urinary bladder cancer	0.00023	0.00106	CcSEcCtD
Orlistat—Depression—Methotrexate—urinary bladder cancer	0.000229	0.00106	CcSEcCtD
Orlistat—Gastritis—Doxorubicin—urinary bladder cancer	0.000228	0.00105	CcSEcCtD
Orlistat—Pain—Cisplatin—urinary bladder cancer	0.000228	0.00105	CcSEcCtD
Orlistat—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000226	0.00104	CcSEcCtD
Orlistat—Renal failure—Methotrexate—urinary bladder cancer	0.000226	0.00104	CcSEcCtD
Orlistat—Dizziness—Thiotepa—urinary bladder cancer	0.000225	0.00104	CcSEcCtD
Orlistat—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000225	0.00104	CcSEcCtD
Orlistat—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000224	0.00103	CcSEcCtD
Orlistat—Urticaria—Fluorouracil—urinary bladder cancer	0.000224	0.00103	CcSEcCtD
Orlistat—Influenza—Doxorubicin—urinary bladder cancer	0.000223	0.00103	CcSEcCtD
Orlistat—Asthma—Doxorubicin—urinary bladder cancer	0.000223	0.00103	CcSEcCtD
Orlistat—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000223	0.00103	CcSEcCtD
Orlistat—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00022	0.00102	CcSEcCtD
Orlistat—Paraesthesia—Etoposide—urinary bladder cancer	0.00022	0.00101	CcSEcCtD
Orlistat—Pancreatitis—Doxorubicin—urinary bladder cancer	0.000219	0.00101	CcSEcCtD
Orlistat—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000217	0.001	CcSEcCtD
Orlistat—Vomiting—Thiotepa—urinary bladder cancer	0.000216	0.000999	CcSEcCtD
Orlistat—Infestation NOS—Epirubicin—urinary bladder cancer	0.000215	0.000992	CcSEcCtD
Orlistat—Infestation—Epirubicin—urinary bladder cancer	0.000215	0.000992	CcSEcCtD
Orlistat—Rash—Thiotepa—urinary bladder cancer	0.000215	0.000991	CcSEcCtD
Orlistat—Dermatitis—Thiotepa—urinary bladder cancer	0.000214	0.00099	CcSEcCtD
Orlistat—Headache—Thiotepa—urinary bladder cancer	0.000213	0.000984	CcSEcCtD
Orlistat—Decreased appetite—Etoposide—urinary bladder cancer	0.000213	0.000981	CcSEcCtD
Orlistat—Renal failure—Epirubicin—urinary bladder cancer	0.000211	0.000975	CcSEcCtD
Orlistat—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000211	0.000974	CcSEcCtD
Orlistat—Body temperature increased—Cisplatin—urinary bladder cancer	0.000211	0.000974	CcSEcCtD
Orlistat—Fatigue—Etoposide—urinary bladder cancer	0.000211	0.000973	CcSEcCtD
Orlistat—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000211	0.000972	CcSEcCtD
Orlistat—Pain—Etoposide—urinary bladder cancer	0.000209	0.000965	CcSEcCtD
Orlistat—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000209	0.000964	CcSEcCtD
Orlistat—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000207	0.000958	CcSEcCtD
Orlistat—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000207	0.000957	CcSEcCtD
Orlistat—Haemoglobin—Methotrexate—urinary bladder cancer	0.000207	0.000956	CcSEcCtD
Orlistat—Haemorrhage—Methotrexate—urinary bladder cancer	0.000206	0.000952	CcSEcCtD
Orlistat—Hepatitis—Methotrexate—urinary bladder cancer	0.000206	0.000952	CcSEcCtD
Orlistat—Asthenia—Gemcitabine—urinary bladder cancer	0.000205	0.000948	CcSEcCtD
Orlistat—Pharyngitis—Methotrexate—urinary bladder cancer	0.000205	0.000944	CcSEcCtD
Orlistat—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000204	0.00094	CcSEcCtD
Orlistat—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000203	0.000938	CcSEcCtD
Orlistat—Pruritus—Gemcitabine—urinary bladder cancer	0.000203	0.000935	CcSEcCtD
Orlistat—Nausea—Thiotepa—urinary bladder cancer	0.000202	0.000933	CcSEcCtD
Orlistat—Urethral disorder—Methotrexate—urinary bladder cancer	0.000202	0.000933	CcSEcCtD
Orlistat—Sinusitis—Epirubicin—urinary bladder cancer	0.000202	0.000931	CcSEcCtD
Orlistat—Feeling abnormal—Etoposide—urinary bladder cancer	0.000202	0.00093	CcSEcCtD
Orlistat—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.0002	0.000923	CcSEcCtD
Orlistat—Pruritus—Fluorouracil—urinary bladder cancer	0.000199	0.00092	CcSEcCtD
Orlistat—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000199	0.000918	CcSEcCtD
Orlistat—Infestation—Doxorubicin—urinary bladder cancer	0.000199	0.000918	CcSEcCtD
Orlistat—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000197	0.000908	CcSEcCtD
Orlistat—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000196	0.000904	CcSEcCtD
Orlistat—Renal failure—Doxorubicin—urinary bladder cancer	0.000195	0.000902	CcSEcCtD
Orlistat—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000195	0.0009	CcSEcCtD
Orlistat—Urticaria—Etoposide—urinary bladder cancer	0.000194	0.000897	CcSEcCtD
Orlistat—Haemoglobin—Epirubicin—urinary bladder cancer	0.000194	0.000895	CcSEcCtD
Orlistat—Abdominal pain—Etoposide—urinary bladder cancer	0.000193	0.000892	CcSEcCtD
Orlistat—Body temperature increased—Etoposide—urinary bladder cancer	0.000193	0.000892	CcSEcCtD
Orlistat—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000193	0.000892	CcSEcCtD
Orlistat—Haemorrhage—Epirubicin—urinary bladder cancer	0.000193	0.000891	CcSEcCtD
Orlistat—Hepatitis—Epirubicin—urinary bladder cancer	0.000193	0.000891	CcSEcCtD
Orlistat—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000193	0.000889	CcSEcCtD
Orlistat—Asthenia—Cisplatin—urinary bladder cancer	0.000192	0.000884	CcSEcCtD
Orlistat—Pharyngitis—Epirubicin—urinary bladder cancer	0.000192	0.000884	CcSEcCtD
Orlistat—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000191	0.000879	CcSEcCtD
Orlistat—Oedema peripheral—Epirubicin—urinary bladder cancer	0.00019	0.000877	CcSEcCtD
Orlistat—Urethral disorder—Epirubicin—urinary bladder cancer	0.000189	0.000873	CcSEcCtD
Orlistat—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000188	0.000868	CcSEcCtD
Orlistat—Sinusitis—Doxorubicin—urinary bladder cancer	0.000187	0.000861	CcSEcCtD
Orlistat—Immune system disorder—Methotrexate—urinary bladder cancer	0.000186	0.00086	CcSEcCtD
Orlistat—Dizziness—Fluorouracil—urinary bladder cancer	0.000186	0.000859	CcSEcCtD
Orlistat—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000186	0.000858	CcSEcCtD
Orlistat—Diarrhoea—Cisplatin—urinary bladder cancer	0.000183	0.000843	CcSEcCtD
Orlistat—Alopecia—Methotrexate—urinary bladder cancer	0.000182	0.000841	CcSEcCtD
Orlistat—Vomiting—Gemcitabine—urinary bladder cancer	0.000182	0.00084	CcSEcCtD
Orlistat—Mental disorder—Methotrexate—urinary bladder cancer	0.000181	0.000834	CcSEcCtD
Orlistat—Rash—Gemcitabine—urinary bladder cancer	0.000181	0.000833	CcSEcCtD
Orlistat—Dermatitis—Gemcitabine—urinary bladder cancer	0.00018	0.000833	CcSEcCtD
Orlistat—Hypersensitivity—Etoposide—urinary bladder cancer	0.00018	0.000832	CcSEcCtD
Orlistat—Malnutrition—Methotrexate—urinary bladder cancer	0.000179	0.000828	CcSEcCtD
Orlistat—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000179	0.000828	CcSEcCtD
Orlistat—Headache—Gemcitabine—urinary bladder cancer	0.000179	0.000828	CcSEcCtD
Orlistat—Vomiting—Fluorouracil—urinary bladder cancer	0.000179	0.000826	CcSEcCtD
Orlistat—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000179	0.000824	CcSEcCtD
Orlistat—Hepatitis—Doxorubicin—urinary bladder cancer	0.000179	0.000824	CcSEcCtD
Orlistat—Rash—Fluorouracil—urinary bladder cancer	0.000178	0.000819	CcSEcCtD
Orlistat—Dermatitis—Fluorouracil—urinary bladder cancer	0.000177	0.000819	CcSEcCtD
Orlistat—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000177	0.000818	CcSEcCtD
Orlistat—Headache—Fluorouracil—urinary bladder cancer	0.000176	0.000814	CcSEcCtD
Orlistat—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000176	0.000814	CcSEcCtD
Orlistat—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000176	0.000812	CcSEcCtD
Orlistat—Dysgeusia—Methotrexate—urinary bladder cancer	0.000176	0.000811	CcSEcCtD
Orlistat—Asthenia—Etoposide—urinary bladder cancer	0.000175	0.00081	CcSEcCtD
Orlistat—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000175	0.000808	CcSEcCtD
Orlistat—Immune system disorder—Epirubicin—urinary bladder cancer	0.000174	0.000804	CcSEcCtD
Orlistat—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000174	0.000803	CcSEcCtD
Orlistat—Back pain—Methotrexate—urinary bladder cancer	0.000174	0.000801	CcSEcCtD
Orlistat—Pruritus—Etoposide—urinary bladder cancer	0.000173	0.000799	CcSEcCtD
Orlistat—Alopecia—Epirubicin—urinary bladder cancer	0.000171	0.000787	CcSEcCtD
Orlistat—Nausea—Gemcitabine—urinary bladder cancer	0.00017	0.000785	CcSEcCtD
Orlistat—Vomiting—Cisplatin—urinary bladder cancer	0.00017	0.000783	CcSEcCtD
Orlistat—Vision blurred—Methotrexate—urinary bladder cancer	0.000169	0.000781	CcSEcCtD
Orlistat—Mental disorder—Epirubicin—urinary bladder cancer	0.000169	0.00078	CcSEcCtD
Orlistat—Rash—Cisplatin—urinary bladder cancer	0.000168	0.000777	CcSEcCtD
Orlistat—Dermatitis—Cisplatin—urinary bladder cancer	0.000168	0.000776	CcSEcCtD
Orlistat—Malnutrition—Epirubicin—urinary bladder cancer	0.000168	0.000775	CcSEcCtD
Orlistat—Diarrhoea—Etoposide—urinary bladder cancer	0.000167	0.000772	CcSEcCtD
Orlistat—Nausea—Fluorouracil—urinary bladder cancer	0.000167	0.000772	CcSEcCtD
Orlistat—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000167	0.000769	CcSEcCtD
Orlistat—Flatulence—Epirubicin—urinary bladder cancer	0.000166	0.000764	CcSEcCtD
Orlistat—Dysgeusia—Epirubicin—urinary bladder cancer	0.000164	0.000759	CcSEcCtD
Orlistat—Back pain—Epirubicin—urinary bladder cancer	0.000162	0.00075	CcSEcCtD
Orlistat—Malaise—Methotrexate—urinary bladder cancer	0.000162	0.000747	CcSEcCtD
Orlistat—Dizziness—Etoposide—urinary bladder cancer	0.000162	0.000746	CcSEcCtD
Orlistat—Muscle spasms—Epirubicin—urinary bladder cancer	0.000161	0.000745	CcSEcCtD
Orlistat—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000161	0.000744	CcSEcCtD
Orlistat—Vertigo—Methotrexate—urinary bladder cancer	0.000161	0.000744	CcSEcCtD
Orlistat—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000161	0.000743	CcSEcCtD
Orlistat—Nausea—Cisplatin—urinary bladder cancer	0.000159	0.000732	CcSEcCtD
Orlistat—Vision blurred—Epirubicin—urinary bladder cancer	0.000158	0.000731	CcSEcCtD
Orlistat—Alopecia—Doxorubicin—urinary bladder cancer	0.000158	0.000728	CcSEcCtD
Orlistat—Cough—Methotrexate—urinary bladder cancer	0.000157	0.000723	CcSEcCtD
Orlistat—Mental disorder—Doxorubicin—urinary bladder cancer	0.000156	0.000722	CcSEcCtD
Orlistat—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000156	0.000719	CcSEcCtD
Orlistat—Convulsion—Methotrexate—urinary bladder cancer	0.000156	0.000718	CcSEcCtD
Orlistat—Vomiting—Etoposide—urinary bladder cancer	0.000155	0.000718	CcSEcCtD
Orlistat—Malnutrition—Doxorubicin—urinary bladder cancer	0.000155	0.000717	CcSEcCtD
Orlistat—Rash—Etoposide—urinary bladder cancer	0.000154	0.000712	CcSEcCtD
Orlistat—Dermatitis—Etoposide—urinary bladder cancer	0.000154	0.000711	CcSEcCtD
Orlistat—Headache—Etoposide—urinary bladder cancer	0.000153	0.000707	CcSEcCtD
Orlistat—Flatulence—Doxorubicin—urinary bladder cancer	0.000153	0.000707	CcSEcCtD
Orlistat—Chest pain—Methotrexate—urinary bladder cancer	0.000153	0.000705	CcSEcCtD
Orlistat—Myalgia—Methotrexate—urinary bladder cancer	0.000153	0.000705	CcSEcCtD
Orlistat—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000152	0.000702	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000152	0.0007	CcSEcCtD
Orlistat—Malaise—Epirubicin—urinary bladder cancer	0.000151	0.000699	CcSEcCtD
Orlistat—Discomfort—Methotrexate—urinary bladder cancer	0.000151	0.000697	CcSEcCtD
Orlistat—Vertigo—Epirubicin—urinary bladder cancer	0.000151	0.000697	CcSEcCtD
Orlistat—Back pain—Doxorubicin—urinary bladder cancer	0.00015	0.000694	CcSEcCtD
Orlistat—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000149	0.00069	CcSEcCtD
Orlistat—Palpitations—Epirubicin—urinary bladder cancer	0.000148	0.000685	CcSEcCtD
Orlistat—Cough—Epirubicin—urinary bladder cancer	0.000147	0.000676	CcSEcCtD
Orlistat—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000146	0.000676	CcSEcCtD
Orlistat—Vision blurred—Doxorubicin—urinary bladder cancer	0.000146	0.000676	CcSEcCtD
Orlistat—Convulsion—Epirubicin—urinary bladder cancer	0.000146	0.000672	CcSEcCtD
Orlistat—Infection—Methotrexate—urinary bladder cancer	0.000146	0.000672	CcSEcCtD
Orlistat—Nausea—Etoposide—urinary bladder cancer	0.000145	0.00067	CcSEcCtD
Orlistat—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000144	0.000666	CcSEcCtD
Orlistat—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000144	0.000663	CcSEcCtD
Orlistat—Chest pain—Epirubicin—urinary bladder cancer	0.000143	0.00066	CcSEcCtD
Orlistat—Myalgia—Epirubicin—urinary bladder cancer	0.000143	0.00066	CcSEcCtD
Orlistat—Anxiety—Epirubicin—urinary bladder cancer	0.000143	0.000658	CcSEcCtD
Orlistat—Skin disorder—Methotrexate—urinary bladder cancer	0.000142	0.000657	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000142	0.000655	CcSEcCtD
Orlistat—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000142	0.000654	CcSEcCtD
Orlistat—Discomfort—Epirubicin—urinary bladder cancer	0.000141	0.000652	CcSEcCtD
Orlistat—Malaise—Doxorubicin—urinary bladder cancer	0.00014	0.000647	CcSEcCtD
Orlistat—Dry mouth—Epirubicin—urinary bladder cancer	0.00014	0.000645	CcSEcCtD
Orlistat—Vertigo—Doxorubicin—urinary bladder cancer	0.00014	0.000644	CcSEcCtD
Orlistat—Palpitations—Doxorubicin—urinary bladder cancer	0.000137	0.000634	CcSEcCtD
Orlistat—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000137	0.000633	CcSEcCtD
Orlistat—Oedema—Epirubicin—urinary bladder cancer	0.000137	0.000633	CcSEcCtD
Orlistat—Infection—Epirubicin—urinary bladder cancer	0.000136	0.000629	CcSEcCtD
Orlistat—Cough—Doxorubicin—urinary bladder cancer	0.000136	0.000626	CcSEcCtD
Orlistat—Convulsion—Doxorubicin—urinary bladder cancer	0.000135	0.000622	CcSEcCtD
Orlistat—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000134	0.00062	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000133	0.000616	CcSEcCtD
Orlistat—Skin disorder—Epirubicin—urinary bladder cancer	0.000133	0.000615	CcSEcCtD
Orlistat—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000133	0.000612	CcSEcCtD
Orlistat—Insomnia—Methotrexate—urinary bladder cancer	0.000132	0.000611	CcSEcCtD
Orlistat—Chest pain—Doxorubicin—urinary bladder cancer	0.000132	0.000611	CcSEcCtD
Orlistat—Myalgia—Doxorubicin—urinary bladder cancer	0.000132	0.000611	CcSEcCtD
Orlistat—Anxiety—Doxorubicin—urinary bladder cancer	0.000132	0.000609	CcSEcCtD
Orlistat—Paraesthesia—Methotrexate—urinary bladder cancer	0.000132	0.000607	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000131	0.000606	CcSEcCtD
Orlistat—Discomfort—Doxorubicin—urinary bladder cancer	0.000131	0.000603	CcSEcCtD
Orlistat—Dry mouth—Doxorubicin—urinary bladder cancer	0.000129	0.000597	CcSEcCtD
Orlistat—Dyspepsia—Methotrexate—urinary bladder cancer	0.000129	0.000595	CcSEcCtD
Orlistat—Decreased appetite—Methotrexate—urinary bladder cancer	0.000127	0.000588	CcSEcCtD
Orlistat—Oedema—Doxorubicin—urinary bladder cancer	0.000127	0.000585	CcSEcCtD
Orlistat—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000127	0.000585	CcSEcCtD
Orlistat—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000126	0.000584	CcSEcCtD
Orlistat—Fatigue—Methotrexate—urinary bladder cancer	0.000126	0.000583	CcSEcCtD
Orlistat—Infection—Doxorubicin—urinary bladder cancer	0.000126	0.000582	CcSEcCtD
Orlistat—Pain—Methotrexate—urinary bladder cancer	0.000125	0.000578	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000125	0.000576	CcSEcCtD
Orlistat—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000124	0.000574	CcSEcCtD
Orlistat—Insomnia—Epirubicin—urinary bladder cancer	0.000124	0.000572	CcSEcCtD
Orlistat—Skin disorder—Doxorubicin—urinary bladder cancer	0.000123	0.000569	CcSEcCtD
Orlistat—Paraesthesia—Epirubicin—urinary bladder cancer	0.000123	0.000568	CcSEcCtD
Orlistat—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000123	0.000566	CcSEcCtD
Orlistat—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000121	0.000557	CcSEcCtD
Orlistat—Dyspepsia—Epirubicin—urinary bladder cancer	0.000121	0.000557	CcSEcCtD
Orlistat—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.00012	0.000553	CcSEcCtD
Orlistat—Decreased appetite—Epirubicin—urinary bladder cancer	0.000119	0.00055	CcSEcCtD
Orlistat—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000118	0.000546	CcSEcCtD
Orlistat—Fatigue—Epirubicin—urinary bladder cancer	0.000118	0.000545	CcSEcCtD
Orlistat—Pain—Epirubicin—urinary bladder cancer	0.000117	0.000541	CcSEcCtD
Orlistat—Urticaria—Methotrexate—urinary bladder cancer	0.000116	0.000537	CcSEcCtD
Orlistat—Abdominal pain—Methotrexate—urinary bladder cancer	0.000116	0.000534	CcSEcCtD
Orlistat—Body temperature increased—Methotrexate—urinary bladder cancer	0.000116	0.000534	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000116	0.000533	CcSEcCtD
Orlistat—Insomnia—Doxorubicin—urinary bladder cancer	0.000115	0.000529	CcSEcCtD
Orlistat—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000114	0.000526	CcSEcCtD
Orlistat—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000113	0.000521	CcSEcCtD
Orlistat—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000112	0.000517	CcSEcCtD
Orlistat—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000112	0.000515	CcSEcCtD
Orlistat—Decreased appetite—Doxorubicin—urinary bladder cancer	0.00011	0.000509	CcSEcCtD
Orlistat—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.00011	0.000505	CcSEcCtD
Orlistat—Fatigue—Doxorubicin—urinary bladder cancer	0.000109	0.000505	CcSEcCtD
Orlistat—Urticaria—Epirubicin—urinary bladder cancer	0.000109	0.000503	CcSEcCtD
Orlistat—Pain—Doxorubicin—urinary bladder cancer	0.000108	0.000501	CcSEcCtD
Orlistat—Abdominal pain—Epirubicin—urinary bladder cancer	0.000108	0.0005	CcSEcCtD
Orlistat—Body temperature increased—Epirubicin—urinary bladder cancer	0.000108	0.0005	CcSEcCtD
Orlistat—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000108	0.000498	CcSEcCtD
Orlistat—DAGLB—Hemostasis—HRAS—urinary bladder cancer	0.000105	0.000698	CbGpPWpGaD
Orlistat—Asthenia—Methotrexate—urinary bladder cancer	0.000105	0.000485	CcSEcCtD
Orlistat—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000105	0.000482	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	0.000104	0.000688	CbGpPWpGaD
Orlistat—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000104	0.000479	CcSEcCtD
Orlistat—PNLIP—Metabolism—ERCC2—urinary bladder cancer	0.000104	0.000687	CbGpPWpGaD
Orlistat—Pruritus—Methotrexate—urinary bladder cancer	0.000104	0.000478	CcSEcCtD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—MYC—urinary bladder cancer	0.000103	0.000685	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000103	0.000683	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000103	0.000683	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—S100B—urinary bladder cancer	0.000103	0.00068	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP4B1—urinary bladder cancer	0.000102	0.000675	CbGpPWpGaD
Orlistat—FASN—Metabolism—NQO1—urinary bladder cancer	0.000102	0.000675	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	0.000102	0.000673	CbGpPWpGaD
Orlistat—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000101	0.000466	CcSEcCtD
Orlistat—Urticaria—Doxorubicin—urinary bladder cancer	0.000101	0.000465	CcSEcCtD
Orlistat—Body temperature increased—Doxorubicin—urinary bladder cancer	0.0001	0.000463	CcSEcCtD
Orlistat—Abdominal pain—Doxorubicin—urinary bladder cancer	0.0001	0.000463	CcSEcCtD
Orlistat—Diarrhoea—Methotrexate—urinary bladder cancer	0.0001	0.000463	CcSEcCtD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	9.98e-05	0.000661	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.88e-05	0.000655	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—IL2—urinary bladder cancer	9.85e-05	0.000653	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—IL2—urinary bladder cancer	9.85e-05	0.000653	CbGpPWpGaD
Orlistat—Asthenia—Epirubicin—urinary bladder cancer	9.84e-05	0.000454	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—TERT—urinary bladder cancer	9.81e-05	0.00065	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TERT—urinary bladder cancer	9.81e-05	0.00065	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—MTHFR—urinary bladder cancer	9.75e-05	0.000646	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—IFNA2—urinary bladder cancer	9.71e-05	0.000644	CbGpPWpGaD
Orlistat—Pruritus—Epirubicin—urinary bladder cancer	9.7e-05	0.000448	CcSEcCtD
Orlistat—Dizziness—Methotrexate—urinary bladder cancer	9.69e-05	0.000447	CcSEcCtD
Orlistat—PLA2G4A—Metabolism—SLC19A1—urinary bladder cancer	9.62e-05	0.000638	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—KRAS—urinary bladder cancer	9.54e-05	0.000633	CbGpPWpGaD
Orlistat—Diarrhoea—Epirubicin—urinary bladder cancer	9.38e-05	0.000433	CcSEcCtD
Orlistat—PLA2G4A—Metabolism—PRSS3—urinary bladder cancer	9.38e-05	0.000622	CbGpPWpGaD
Orlistat—Hypersensitivity—Doxorubicin—urinary bladder cancer	9.35e-05	0.000431	CcSEcCtD
Orlistat—FASN—Disease—NCOR1—urinary bladder cancer	9.32e-05	0.000618	CbGpPWpGaD
Orlistat—Vomiting—Methotrexate—urinary bladder cancer	9.31e-05	0.00043	CcSEcCtD
Orlistat—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	9.29e-05	0.000615	CbGpPWpGaD
Orlistat—Rash—Methotrexate—urinary bladder cancer	9.24e-05	0.000426	CcSEcCtD
Orlistat—Dermatitis—Methotrexate—urinary bladder cancer	9.23e-05	0.000426	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—NCOR1—urinary bladder cancer	9.22e-05	0.000611	CbGpPWpGaD
Orlistat—Headache—Methotrexate—urinary bladder cancer	9.18e-05	0.000424	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	9.17e-05	0.000608	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	9.16e-05	0.000607	CbGpPWpGaD
Orlistat—Asthenia—Doxorubicin—urinary bladder cancer	9.1e-05	0.00042	CcSEcCtD
Orlistat—PNLIP—Disease—CREBBP—urinary bladder cancer	9.07e-05	0.000601	CbGpPWpGaD
Orlistat—Dizziness—Epirubicin—urinary bladder cancer	9.07e-05	0.000418	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—FGFR3—urinary bladder cancer	9e-05	0.000597	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—FGFR3—urinary bladder cancer	9e-05	0.000597	CbGpPWpGaD
Orlistat—Pruritus—Doxorubicin—urinary bladder cancer	8.97e-05	0.000414	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	8.87e-05	0.000588	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	8.85e-05	0.000587	CbGpPWpGaD
Orlistat—FASN—Disease—ERCC2—urinary bladder cancer	8.76e-05	0.000581	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—ESR1—urinary bladder cancer	8.74e-05	0.000579	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—ESR1—urinary bladder cancer	8.74e-05	0.000579	CbGpPWpGaD
Orlistat—Vomiting—Epirubicin—urinary bladder cancer	8.72e-05	0.000402	CcSEcCtD
Orlistat—Nausea—Methotrexate—urinary bladder cancer	8.7e-05	0.000402	CcSEcCtD
Orlistat—Diarrhoea—Doxorubicin—urinary bladder cancer	8.68e-05	0.000401	CcSEcCtD
Orlistat—Rash—Epirubicin—urinary bladder cancer	8.64e-05	0.000399	CcSEcCtD
Orlistat—Dermatitis—Epirubicin—urinary bladder cancer	8.64e-05	0.000399	CcSEcCtD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.62e-05	0.000571	CbGpPWpGaD
Orlistat—Headache—Epirubicin—urinary bladder cancer	8.59e-05	0.000396	CcSEcCtD
Orlistat—FASN—Metabolism—GSTP1—urinary bladder cancer	8.49e-05	0.000563	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	8.44e-05	0.00056	CbGpPWpGaD
Orlistat—Dizziness—Doxorubicin—urinary bladder cancer	8.39e-05	0.000387	CcSEcCtD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	8.37e-05	0.000555	CbGpPWpGaD
Orlistat—FASN—Disease—MTHFR—urinary bladder cancer	8.24e-05	0.000546	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.22e-05	0.000545	CbGpPWpGaD
Orlistat—FASN—Disease—TERT—urinary bladder cancer	8.21e-05	0.000544	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	8.21e-05	0.000544	CbGpPWpGaD
Orlistat—PNLIP—Disease—RHOA—urinary bladder cancer	8.2e-05	0.000544	CbGpPWpGaD
Orlistat—Nausea—Epirubicin—urinary bladder cancer	8.14e-05	0.000376	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—TERT—urinary bladder cancer	8.13e-05	0.000539	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—HRAS—urinary bladder cancer	8.11e-05	0.000538	CbGpPWpGaD
Orlistat—Vomiting—Doxorubicin—urinary bladder cancer	8.06e-05	0.000372	CcSEcCtD
Orlistat—Rash—Doxorubicin—urinary bladder cancer	8e-05	0.000369	CcSEcCtD
Orlistat—Dermatitis—Doxorubicin—urinary bladder cancer	7.99e-05	0.000369	CcSEcCtD
Orlistat—Headache—Doxorubicin—urinary bladder cancer	7.95e-05	0.000367	CcSEcCtD
Orlistat—PNLIP—Metabolism—PPARG—urinary bladder cancer	7.9e-05	0.000524	CbGpPWpGaD
Orlistat—FASN—Metabolism—TYMS—urinary bladder cancer	7.9e-05	0.000523	CbGpPWpGaD
Orlistat—FASN—Metabolism—NCOR1—urinary bladder cancer	7.8e-05	0.000517	CbGpPWpGaD
Orlistat—FASN—Metabolism—GSTM1—urinary bladder cancer	7.8e-05	0.000517	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CREBBP—urinary bladder cancer	7.66e-05	0.000508	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CREBBP—urinary bladder cancer	7.66e-05	0.000508	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—CREBBP—urinary bladder cancer	7.59e-05	0.000503	CbGpPWpGaD
Orlistat—PNLIP—Disease—ERBB2—urinary bladder cancer	7.59e-05	0.000503	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IGF1—urinary bladder cancer	7.57e-05	0.000502	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IGF1—urinary bladder cancer	7.57e-05	0.000502	CbGpPWpGaD
Orlistat—FASN—Disease—FGFR3—urinary bladder cancer	7.54e-05	0.000499	CbGpPWpGaD
Orlistat—Nausea—Doxorubicin—urinary bladder cancer	7.53e-05	0.000348	CcSEcCtD
Orlistat—DAGLA—Signaling by GPCR—EGFR—urinary bladder cancer	7.53e-05	0.000499	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—EGFR—urinary bladder cancer	7.53e-05	0.000499	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	7.52e-05	0.000498	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—TYMP—urinary bladder cancer	7.5e-05	0.000497	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HDAC4—urinary bladder cancer	7.48e-05	0.000496	CbGpPWpGaD
Orlistat—FASN—Metabolism—GPX1—urinary bladder cancer	7.47e-05	0.000495	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—FGFR3—urinary bladder cancer	7.46e-05	0.000494	CbGpPWpGaD
Orlistat—PNLIP—Disease—PTGS2—urinary bladder cancer	7.43e-05	0.000492	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	7.42e-05	0.000492	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	7.36e-05	0.000488	CbGpPWpGaD
Orlistat—FASN—Metabolism—ERCC2—urinary bladder cancer	7.34e-05	0.000486	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	7.31e-05	0.000484	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—ESR1—urinary bladder cancer	7.25e-05	0.00048	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	7.2e-05	0.000477	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	7.2e-05	0.000477	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	7.2e-05	0.000477	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—KRAS—urinary bladder cancer	7.11e-05	0.000471	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—KRAS—urinary bladder cancer	7.11e-05	0.000471	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—RHOA—urinary bladder cancer	6.93e-05	0.000459	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—RHOA—urinary bladder cancer	6.93e-05	0.000459	CbGpPWpGaD
Orlistat—FASN—Metabolism—MTHFR—urinary bladder cancer	6.9e-05	0.000457	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PLAU—urinary bladder cancer	6.89e-05	0.000457	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	6.85e-05	0.000454	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	6.8e-05	0.000451	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—NAT2—urinary bladder cancer	6.78e-05	0.000449	CbGpPWpGaD
Orlistat—PNLIP—Disease—CDKN1A—urinary bladder cancer	6.49e-05	0.00043	CbGpPWpGaD
Orlistat—PNLIP—Disease—PTEN—urinary bladder cancer	6.48e-05	0.000429	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—ERBB2—urinary bladder cancer	6.42e-05	0.000425	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—ERBB2—urinary bladder cancer	6.42e-05	0.000425	CbGpPWpGaD
Orlistat—FASN—Disease—CREBBP—urinary bladder cancer	6.42e-05	0.000425	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CREBBP—urinary bladder cancer	6.35e-05	0.000421	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IGF1—urinary bladder cancer	6.27e-05	0.000416	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GLI1—urinary bladder cancer	6.27e-05	0.000416	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PTGS2—urinary bladder cancer	6.22e-05	0.000412	CbGpPWpGaD
Orlistat—PNLIP—Disease—EP300—urinary bladder cancer	6.18e-05	0.000409	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CXCL8—urinary bladder cancer	6.09e-05	0.000403	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CXCL8—urinary bladder cancer	6.09e-05	0.000403	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—HRAS—urinary bladder cancer	6.05e-05	0.000401	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—HRAS—urinary bladder cancer	6.05e-05	0.000401	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	6.04e-05	0.0004	CbGpPWpGaD
Orlistat—PNLIP—Disease—SRC—urinary bladder cancer	6.01e-05	0.000398	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—RRM2—urinary bladder cancer	5.85e-05	0.000388	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL2—urinary bladder cancer	5.82e-05	0.000385	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL2—urinary bladder cancer	5.82e-05	0.000385	CbGpPWpGaD
Orlistat—FASN—Disease—RHOA—urinary bladder cancer	5.8e-05	0.000385	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—RHOA—urinary bladder cancer	5.74e-05	0.000381	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—CREBBP—urinary bladder cancer	5.69e-05	0.000377	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CCND1—urinary bladder cancer	5.67e-05	0.000376	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CCND1—urinary bladder cancer	5.67e-05	0.000376	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—IGF1—urinary bladder cancer	5.62e-05	0.000372	CbGpPWpGaD
Orlistat—FASN—Metabolism—PPARG—urinary bladder cancer	5.59e-05	0.000371	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MMP9—urinary bladder cancer	5.5e-05	0.000365	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MMP9—urinary bladder cancer	5.5e-05	0.000365	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CDKN1A—urinary bladder cancer	5.49e-05	0.000364	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CDKN1A—urinary bladder cancer	5.49e-05	0.000364	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PTEN—urinary bladder cancer	5.47e-05	0.000363	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PTEN—urinary bladder cancer	5.47e-05	0.000363	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PTEN—urinary bladder cancer	5.42e-05	0.000359	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—HPGDS—urinary bladder cancer	5.42e-05	0.000359	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ENO2—urinary bladder cancer	5.42e-05	0.000359	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.39e-05	0.000357	CbGpPWpGaD
Orlistat—PNLIP—Disease—MYC—urinary bladder cancer	5.38e-05	0.000357	CbGpPWpGaD
Orlistat—FASN—Metabolism—CREBBP—urinary bladder cancer	5.37e-05	0.000356	CbGpPWpGaD
Orlistat—FASN—Disease—ERBB2—urinary bladder cancer	5.37e-05	0.000356	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—ERBB2—urinary bladder cancer	5.32e-05	0.000352	CbGpPWpGaD
Orlistat—PNLIP—Disease—EGFR—urinary bladder cancer	5.26e-05	0.000349	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GSTT1—urinary bladder cancer	5.26e-05	0.000348	CbGpPWpGaD
Orlistat—FASN—Disease—PTGS2—urinary bladder cancer	5.25e-05	0.000348	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—EP300—urinary bladder cancer	5.22e-05	0.000346	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—EP300—urinary bladder cancer	5.22e-05	0.000346	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.18e-05	0.000343	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—EP300—urinary bladder cancer	5.17e-05	0.000343	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—RHOA—urinary bladder cancer	5.14e-05	0.000341	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—SRC—urinary bladder cancer	5.08e-05	0.000336	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—SRC—urinary bladder cancer	5.08e-05	0.000336	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CXCL8—urinary bladder cancer	5.04e-05	0.000334	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	4.99e-05	0.000331	CbGpPWpGaD
Orlistat—PNLIP—Disease—KRAS—urinary bladder cancer	4.97e-05	0.00033	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	4.92e-05	0.000326	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL2—urinary bladder cancer	4.82e-05	0.000319	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CCND1—urinary bladder cancer	4.7e-05	0.000311	CbGpPWpGaD
Orlistat—FASN—Disease—CDKN1A—urinary bladder cancer	4.59e-05	0.000304	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	4.59e-05	0.000304	CbGpPWpGaD
Orlistat—FASN—Disease—PTEN—urinary bladder cancer	4.58e-05	0.000304	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MMP9—urinary bladder cancer	4.56e-05	0.000302	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MYC—urinary bladder cancer	4.55e-05	0.000301	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MYC—urinary bladder cancer	4.55e-05	0.000301	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CDKN1A—urinary bladder cancer	4.54e-05	0.000301	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PTEN—urinary bladder cancer	4.53e-05	0.000301	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	4.52e-05	0.0003	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—EGFR—urinary bladder cancer	4.45e-05	0.000295	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—EGFR—urinary bladder cancer	4.45e-05	0.000295	CbGpPWpGaD
Orlistat—FASN—Metabolism—PTGS2—urinary bladder cancer	4.4e-05	0.000292	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—NQO1—urinary bladder cancer	4.37e-05	0.00029	CbGpPWpGaD
Orlistat—FASN—Disease—EP300—urinary bladder cancer	4.37e-05	0.00029	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—EP300—urinary bladder cancer	4.32e-05	0.000287	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—IL2—urinary bladder cancer	4.32e-05	0.000286	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RBX1—urinary bladder cancer	4.3e-05	0.000285	CbGpPWpGaD
Orlistat—FASN—Disease—SRC—urinary bladder cancer	4.25e-05	0.000282	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.24e-05	0.000281	CbGpPWpGaD
Orlistat—PNLIP—Disease—HRAS—urinary bladder cancer	4.23e-05	0.00028	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SRC—urinary bladder cancer	4.21e-05	0.000279	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—KRAS—urinary bladder cancer	4.2e-05	0.000279	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—KRAS—urinary bladder cancer	4.2e-05	0.000279	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TSC1—urinary bladder cancer	4.04e-05	0.000268	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—EP300—urinary bladder cancer	3.87e-05	0.000257	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—JAG1—urinary bladder cancer	3.85e-05	0.000255	CbGpPWpGaD
Orlistat—FASN—Metabolism—PTEN—urinary bladder cancer	3.84e-05	0.000254	CbGpPWpGaD
Orlistat—FASN—Disease—MYC—urinary bladder cancer	3.81e-05	0.000252	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MYC—urinary bladder cancer	3.77e-05	0.00025	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—SRC—urinary bladder cancer	3.77e-05	0.00025	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TP53—urinary bladder cancer	3.73e-05	0.000248	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TP53—urinary bladder cancer	3.73e-05	0.000248	CbGpPWpGaD
Orlistat—FASN—Disease—EGFR—urinary bladder cancer	3.72e-05	0.000247	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.7e-05	0.000245	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—EGFR—urinary bladder cancer	3.69e-05	0.000244	CbGpPWpGaD
Orlistat—FASN—Metabolism—EP300—urinary bladder cancer	3.66e-05	0.000243	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GSTP1—urinary bladder cancer	3.64e-05	0.000242	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—HRAS—urinary bladder cancer	3.57e-05	0.000237	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—HRAS—urinary bladder cancer	3.57e-05	0.000237	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.53e-05	0.000234	CbGpPWpGaD
Orlistat—FASN—Disease—KRAS—urinary bladder cancer	3.52e-05	0.000233	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—KRAS—urinary bladder cancer	3.48e-05	0.000231	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—TYMS—urinary bladder cancer	3.39e-05	0.000225	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—NCOR1—urinary bladder cancer	3.35e-05	0.000222	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GSTM1—urinary bladder cancer	3.35e-05	0.000222	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GPX1—urinary bladder cancer	3.21e-05	0.000213	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ERCC2—urinary bladder cancer	3.15e-05	0.000209	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—KRAS—urinary bladder cancer	3.12e-05	0.000207	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—S100B—urinary bladder cancer	3.11e-05	0.000206	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TP53—urinary bladder cancer	3.09e-05	0.000205	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	3.06e-05	0.000203	CbGpPWpGaD
Orlistat—FASN—Disease—HRAS—urinary bladder cancer	2.99e-05	0.000198	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—MTHFR—urinary bladder cancer	2.96e-05	0.000196	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—HRAS—urinary bladder cancer	2.96e-05	0.000196	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—RHOA—urinary bladder cancer	2.95e-05	0.000196	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.9e-05	0.000192	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.9e-05	0.000192	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NCOR1—urinary bladder cancer	2.8e-05	0.000186	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TP53—urinary bladder cancer	2.77e-05	0.000184	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.65e-05	0.000176	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—HRAS—urinary bladder cancer	2.65e-05	0.000176	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CXCL8—urinary bladder cancer	2.59e-05	0.000172	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL2—urinary bladder cancer	2.48e-05	0.000164	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TERT—urinary bladder cancer	2.47e-05	0.000164	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PPARG—urinary bladder cancer	2.4e-05	0.000159	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	2.39e-05	0.000158	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CREBBP—urinary bladder cancer	2.31e-05	0.000153	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FGFR3—urinary bladder cancer	2.26e-05	0.00015	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.25e-05	0.000149	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ESR1—urinary bladder cancer	2.2e-05	0.000146	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.2e-05	0.000146	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CREBBP—urinary bladder cancer	1.93e-05	0.000128	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IGF1—urinary bladder cancer	1.9e-05	0.000126	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—EGFR—urinary bladder cancer	1.89e-05	0.000126	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTGS2—urinary bladder cancer	1.89e-05	0.000125	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—KRAS—urinary bladder cancer	1.79e-05	0.000119	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.76e-05	0.000116	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RHOA—urinary bladder cancer	1.74e-05	0.000116	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTEN—urinary bladder cancer	1.65e-05	0.000109	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ERBB2—urinary bladder cancer	1.61e-05	0.000107	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.59e-05	0.000105	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—EP300—urinary bladder cancer	1.57e-05	0.000104	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CXCL8—urinary bladder cancer	1.53e-05	0.000101	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—HRAS—urinary bladder cancer	1.52e-05	0.000101	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL2—urinary bladder cancer	1.46e-05	9.7e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCND1—urinary bladder cancer	1.43e-05	9.45e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MMP9—urinary bladder cancer	1.38e-05	9.18e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.38e-05	9.15e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTEN—urinary bladder cancer	1.38e-05	9.12e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.37e-05	9.09e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EP300—urinary bladder cancer	1.31e-05	8.7e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SRC—urinary bladder cancer	1.28e-05	8.46e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.27e-05	8.41e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.27e-05	8.41e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.23e-05	8.16e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MYC—urinary bladder cancer	1.14e-05	7.58e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EGFR—urinary bladder cancer	1.12e-05	7.42e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KRAS—urinary bladder cancer	1.06e-05	7.01e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.02e-05	6.78e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TP53—urinary bladder cancer	9.4e-06	6.23e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HRAS—urinary bladder cancer	8.99e-06	5.96e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	8.53e-06	5.66e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TYMS—urinary bladder cancer	7.93e-06	5.26e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	7.84e-06	5.2e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	7.84e-06	5.2e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GPX1—urinary bladder cancer	7.51e-06	4.98e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	7.37e-06	4.89e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	6.93e-06	4.59e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PPARG—urinary bladder cancer	5.62e-06	3.73e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	5.4e-06	3.58e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	4.42e-06	2.93e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.86e-06	2.56e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.68e-06	2.44e-05	CbGpPWpGaD
